Loading...
NPI 1427595354 · Hollywood, FL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
E-lab Of Florida Inc. is a clinical medical laboratory provider located in Hollywood, Florida. This profile covers 26 Medicare and 76 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | E-lab Of Florida Inc. |
| Address | 6100 Hollywood Blvd |
| City | Hollywood |
| State | FL |
| ZIP | 33024 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 30, 2017 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $7.4M |
| Medicaid | $15.2K |
E-LAB OF FLORIDA INC. is a Medicare-dominated clinical laboratory: reported Total Medicare revenue is $7.4M versus Total Medicaid revenue of $15.2K, indicating the provider’s commercial footprint in this dataset is overwhelmingly weighted to Medicare rather than Medicaid. The NPI was enumerated 2017-01-30 (~9 years ago), so this billing profile reflects several years of post-enrollment activity.
Revenue concentration on Medicare is meaningful but not extreme: the precomputed top 3 Medicare codes by revenue account for 31.3% of this provider's total Medicare revenue, with K1034, 81471, and 81490 the largest contributors. These top Medicare codes combine high-volume COVID test claims (K1034) with multiple high-dollar genomic and biomarker panel codes (81471, 81490), indicating a mixed operating model that includes both high-throughput infectious disease testing and specialized genetic diagnostics.
81471 stands out as a national specialty outlier: it generated $764.3K in Medicare revenue and the file notes it ranks #1 of 5 providers nationally and is classified as "notably above typical national volume." This suggests E-LAB is a major national participant for that specific high-complexity genetic panel, likely reflecting either a niche service line or a referral/testing contract that drives outsized volume for that code.
K1034 drives material Medicare volume but is characterized as routine at scale: K1034 accounts for $824.2K (11.1% of Medicare revenue) with 68.7K claims and is described as "typical, unremarkable volume for this code" despite its large absolute claim count. That combination implies the lab processes very high counts of lower-paid infectious disease/self-test processing alongside its higher-revenue genetic testing work.
On Medicaid the revenue picture is concentrated in COVID-related codes: the top 3 Medicaid codes by revenue account for 94.2% of Medicaid revenue, with U0003 responsible for $9.9K (64.1% of Medicaid revenue), G2023 $2.6K (17.0%), and U0005 $2K (13.1%). These shares indicate the provider’s Medicaid activity is effectively dominated by SARS-CoV-2 testing and specimen-collection services rather than the higher-priced genomic tests that drive Medicare revenue.
Competitive standing varies by code: for Medicare genomic codes such as 81490 (ranks #6 of 20, 74th percentile) and multiple 81xxx-series tests (most labeled "typical, unremarkable volume" at mid-to-high percentiles), E-LAB is a credible regional/niche competitor but generally not a broad national consolidator except for 81471 where it is a clear outlier. In Medicaid, U0003 and related COVID codes rank in mid-to-upper state percentiles (e.g., U0003 at the 73rd percentile in-state), indicating active participation statewide but not dominance across Florida.
The payer-reporting detail shows potential reporting or payment artifacts in Medicaid: many routine lab analyte and specimen codes (for example 80053, 80061, 36415 and numerous others) appear with nonzero claim counts but list $0 avg paid/claim and $0 revenue in the Medicaid extract. This pattern may reflect Medicaid nonpayment, pass-through billing arrangements, or differences in which claim lines generate reimbursed laboratory revenue versus administrative/collection entries and should be validated before drawing operational conclusions.
Operational summary for contracting and utilization review: E-LAB’s Medicare portfolio is anchored by high-dollar genomic panels and a high-volume COVID testing stream, with the top 3 Medicare codes accounting for 31.3% of Medicare revenue, whereas Medicaid revenue is small and overwhelmingly COVID-driven (top 3 = 94.2%). For payers evaluating network value or utilization risk, the lab represents a high-value specialty genomics partner on Medicare, coupled with routine infectious-testing capacity on Medicaid; attention should focus on the outsized position in 81471 and reconciliation of $0-paid Medicaid claim lines.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
26 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 68,690 | $10 | $824.2K |
| 81471 | The lab analyst performs a panel to evaluate the patient specimen for duplication and deletion mutations of at least 60 genes, including the 15 genes that the code descriptor lists, which relate to… | 850 | $900 | $764.3K |
| 81490 | The lab analyst performs the technical lab tests for 12 serum biomarker immunoassays, and carries out an algorithmic analysis using patient data and the lab test results to report a patient disease… | 890 | $820 | $729.2K |
| 81351 | The lab analyst performs the technical lab test on a specimen such as blood to analyze the entire gene sequence for the tumor protein 53 (TP53) gene, which may indicate a diagnosis of Li–Fraumeni… | 890 | $630 | $557.3K |
| 81307 | The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene. | 830 | $660 | $547.6K |
| 81440 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least 100 mitochondrial genes encoded in the nucleus, including 19 specific… | 160 | $3,260 | $531.1K |
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 840 | $590 | $495.1K |
| 81249 | The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene. | 830 | $590 | $489.8K |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 830 | $590 | $485.1K |
| 81223 | The lab analyst performs the technical lab test to analyze the entire gene sequence for cystic fibrosis transmembrane conductance regulator gene, also known as CFTR. | 810 | $490 | $394.6K |
Showing 1–10 of 26
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 26 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
26 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81440 | 4 | 10 | 170 | $3,240 | $658.4K |
| 81307 | 8 | 30 | 320 | $660 | $508.3K |
| 81443 | 5 | 10 | 170 | $2,400 | $481.7K |
| 81321 | 8 | 30 | 430 | $580 | $467.7K |
| 81490 | 2 | 10 | 610 | $820 | $461.1K |
| 81238 | 8 | 20 | 330 | $590 | $440.3K |
| 81419 | 8 | 10 | 90 | $2,400 | $434.1K |
| 81471 | 1 | 10 | 330 | $900 | $388.1K |
| 81249 | 6 | 20 | 290 | $590 | $383.1K |
| 81223 | 7 | 20 | 340 | $490 | $329.3K |
Showing 1–10 of 26
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
76 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 2,480 | $1 | $9.9K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2,630 | $1 | $2.6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 2,040 | $1 | $2K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 150 | $10 | $890 |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 1,650 | $0 | $0 |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 1,450 | $0 | $0 |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 1,290 | $0 | $0 |
| 80076 | The lab analyst performs a hepatic function panel test in which he measures the blood levels of total protein, albumin, alkaline phosphatase, bilirubin, both total and direct, and liver enzymes. | 30 | $0 | $0 |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 20 | $0 | $0 |
| 81000 | The lab analyst inserts a dip stick into a freshly collected urine specimen, removes the dip stick, and shakes off the excess urine. Alternatively, the analyst may place drops of the urine specimen… | 310 | $0 | $0 |
Showing 1–10 of 76
How this provider's Medicaid billing volume and revenue compare to other Florida providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Florida median
76 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 87 | 320 | 750 | $40 | $232.7K |
| 81443 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least 15 genes, such as the 20 gene examples listed in the code descriptor. The… | 6 | 10 | 200 | $440 | $201.7K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 398 | 640 | 4,400 | $10 | $193.4K |
| 83970 | Parathyroid hormone test measures the level of PTH in the blood. This test is done to ascertain the level of calcium and evaluate the parathyroid function. | 403 | 460 | 510 | $50 | $110.2K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 401 | 820 | 1,430 | $1 | $92.8K |
| 83540 | The lab analyst measures the iron level, primarily in serum. Iron is one of the essential elements in the body, and the greatest portion is present combined with hemoglobin within the red blood cells. | 471 | 620 | 690 | $30 | $82.3K |
| 83550 | The lab analyst measures the iron binding capacity, typically in a serum sample. This analyte is an important measurement of the capacity of iron to bind to transferrin. That capacity is also known… | 485 | 550 | 590 | $30 | $79K |
| 84100 | The lab analyst performs a test to evaluate the level of phosphate, which is phosphorus not contained in biological compounds, in a patient specimen such as serum. | 446 | 490 | 1,260 | $10 | $75.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 436 | 450 | 1,380 | $20 | $75.1K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 87 | 340 | 220 | $10 | $67.4K |
Showing 1–10 of 76
Other providers in the same ZIP code as E-lab Of Florida Inc., ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Lovable Family Home Care LLC | FL | Developmentally Disabled Services Day Training Agency | $0 | $83.6M |
| Supra Home Health, Inc. | FL | Home Health Agency | $0 | $23.1M |
| Millenium Clinic, Inc | FL | Community/Behavioral Health Agency | $0 | $17.1M |
| South Broward Hospital District | FL | General Acute Care Hospital | $0 | $15M |
| South Florida Pediatric Homecare Inc. | FL | Home Health Agency | $0 | $13.8M |
| Assisting Broward, LLC | FL | Home Health Agency | $0 | $10M |
| Michel Castillo Madrigal | FL | Family Nurse Practitioner | $818.2K | $0 |
| Michael Hall | FL | Radiation Oncology Physician | $629.6K | $0 |
| Sara Malagold | FL | Clinical Psychologist | $371.4K | $103.3K |
| Ketang Modi | FL | Diagnostic Radiology Physician | $292K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.